DHA does not protect ELOVL4 transgenic mice from retinal degeneration by Li, Feng et al.
DHA does not protect ELOVL4 transgenic mice from retinal
degeneration
1Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK; 2Department of Cell Biology,
University of Oklahoma Health Sciences Center, Oklahoma City, OK; 3Department of Medicine, University of Oklahoma Health
Sciences Center, Oklahoma City, OK; 4Dean A. McGee Eye Institute, Oklahoma City, OK; 5Shiley Eye Center, University of
California San Diego, San Diego, CA
Purpose: Dominant Stargardt macular dystrophy (STGD3) is caused by several different mutations in a gene named
ELOVL4, which shares sequence homologies with a family of genes that encode proteins involved in the ELOngation of
Very  Long  chain  fatty  acids.  Studies  have  suggested  that  patients  with  STGD3  have  aberrant  metabolism  of
docosahexaenoic  acid  (DHA,  22:6n3),  the  major  polyunsaturated  fatty  acid  (PUFA)  in  retinal  rod  outer  segment
membranes. We tested the effect of DHA on the progression of retinal degeneration in transgenic mice that express one
of the mutations identified in STGD3.
Methods: Transgenic mice expressing mutant human ELOVL4 (TG2) were bred to mice expressing the fat-1 protein,
which can convert n6 to n3 PUFA. Mice were maintained on an n3-deficient diet containing 10% safflower oil (SFO,
enriched in n6 PUFA; n6/n3=273) so that four experimental groups were produced that differed only in levels of n3 PUFA
and expression of the hELOVL4 transgene. These groups were identified by genotyping and named Fat1+/TG2+, Fat1–/
TG2+, Fat1+/TG2–, and Fat1–/TG2–. All were continued on the SFO diet for 4 to 16 weeks such that those not expressing
Fat1  would  be  deficient  in  n3  fatty  acids.  At  both  time  points,  animals  were  analyzed  for  retinal  function  by
electroretinography (ERG), photoreceptor cell viability by outer nuclear layer (ONL) thickness measurements, fatty acid
profiles in several tissues, and rhodopsin levels.
Results: Mice expressing the fat-1 transgene had significantly higher levels of n3 PUFA, primarily DHA, in retina, liver,
and plasma lipids at 4 and 16 weeks of age. Retinal DHA levels in fat-1 mice were twice those of controls. By 16 weeks
of age, mice expressing the mutant hELOVL4 transgene had a significantly greater loss of photoreceptor cells, reduced
ERG amplitudes, and lower rhodopsin levels than control mice. There was no effect of retinal fatty acids on the rate of
degeneration of retinas expressing the ELOVL4 transgene.
Conclusions: We found no evidence that high levels of DHA in retinal membranes protected photoreceptor cells
expressing mutant ELOVL4 from retinal degeneration. We conclude that DHA is not beneficial for the treatment of retinal
degeneration in this animal model of human STGD3 macular dystrophy.
In 2001, a 5 bp deletion in a novel gene was identified in
several  families  with  autosomal  dominant  Stargardt-like
macular dystrophy (STGD3). The gene was found to share
homologies throughout the entire sequence with the family of
fatty acid elongases (ELO) [1,2]. The STGD3 gene was named
for elongation of very long chain fatty acids-4 (ELOVL4) and
its protein product was proposed by Zhang et al. [2] to be a
fatty acid elongase. Among the tissues tested, the gene was
expressed in brain, retina, skin, and testis [3]. In the retina,
ELOVL4  was  expressed  at  a  high  level  in  rod  and  cone
photoreceptor  cells  in  human,  mouse,  and  monkey  [2-5].
Karan et al. [6] created a transgenic mouse model of STGD3
disease that expressed human ELOVL4 containing the 5 bp
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deletion. A retinal degeneration was observed in two lines that
correlated with the level of expression of the transgene.
The ELO family of fatty acid elongases is involved in
adding two-carbon units to existing fatty acids to produce fatty
acids  of  chain  lengths  16–38  [7].  These  elongases  are
especially  important  in  the  production  of  long  chain
polyunsaturated fatty acids (LC-PUFA), whose short chain
precursors  must  be  obtained  from  the  diet  [8].
Docosahexaenoic acid (DHA), with 22 carbons and 6 double
bonds (22:6n3), is a member of the n3 family of essential
PUFA  and  the  most  abundant  fatty  acid  found  in  retinal
photoreceptor membranes [9]. Studies over four decades have
demonstrated  the  critical  role  that  DHA  plays  in  the
maintenance of normal structure and function in the retina
[10-21]. Thus, when the STGD3 gene locus was found to have
high sequence homology with the well known ELO family of
fatty acid elongases, the first prediction was that the mutation
in ELOVL4 would affect DHA metabolism [2]. Indeed, some
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Mammals  cannot  synthesize  DHA  de  novo  and  must
therefore depend on a dietary source of preformed DHA or on
elongation of shorter chain PUFA such as α-linolenic acid
(ALA; 18:3n3) [8]. Significant changes in retinal DHA and
other PUFA levels can be effected by dietary restriction of n3
PUFA, especially if started early in pregnancy and continued
during the nursing period and thereafter [25,26]. However,
this involves feeding two different diets to animals born at
different  times  to  different  dams.  Another  approach  to
manipulating retinal PUFA levels was developed by Kang et
al. [27], who created a transgenic mouse that expressed the
fat-1 gene, which encodes an n3 desaturase. Originally cloned
from Caenorhabditis elegans [28], this enzyme efficiently
converts n6 PUFA to n3 PUFA in all tissues of the body,
making it possible to produce membrane lipids with vastly
different  n6:n3  ratios  in  mice  from  the  same  genetic
background fed identical diets. We have recently used these
mice to study the role of DHA in light damage susceptibility
[29].
The  purpose  of  the  present  study  was  to  test  the
hypothesis  that  DHA  slowed  or  prevented  retinal
degeneration in mice that express the mutant hELOVL4 gene
in rod and cone photoreceptor cells. We crossed a transgenic
mouse line with a moderate rate of retinal degeneration (TG2
line [6]) with mice that expressed the fat-1 gene and generated
four predictable groups of experimental animals. All dams and
offspring were fed the same diet, which had high levels of n6
and only traces of n3 PUFA (n6:n3 ratio=273 [29]). The
results showed that high retinal levels of DHA did not protect
the retinas of mice expressing the ELOVL4 transgene from
degeneration.
METHODS
Animals: Fat-1 transgenic male mice carrying a fat-1 gene of
Caenorhabditis  elegans  in  a  C57BL/6J  background  were
kindly provided by Dr. Jing Kang (Department of Medicine,
Massachusetts General Hospital and Harvard Medical School,
Boston, MA). These mice were bred to heterozygous female
mice generated by Karan et al. [6] in a C57BL/6J background
that,  before  breeding,  had  been  fed  a  modified  AIN-76A
Purified Rodent Diet containing 10% safflower oil (SFO;
Dyets  Inc.,  Bethlehem,  PA).  SFO  is  an  edible  seed  oil
consisting  primarily  of  triglycerides  of  linoleic  acid  (LA;
18:2n6), and has very low levels of n3 PUFA and no DHA.
The composition of this diet can be found in Tanito et al.
[29]. Four different groups of mice, Fat1+/TG2+, Fat1–/TG2+,
Fat1+/TG2–, and Fat1–/TG2–, were identified within the same
group of litters by genotyping. The offspring were weaned at
3 weeks of age and maintained on the same SFO diet fed their
parents. Animals were cared for and handled according to the
Association  for  Research  in  Vision  and  Ophthalmology
(ARVO)  statement  for  the  use  of  animals  in  vision  and
ophthalmic  research.  All  protocols  were  approved  by  the
Institutional Animal Care and Use Committee (IACUC) and
comply with the guidelines of the University of Oklahoma
Faculty of Medicine and the Dean McGee Eye Institute for
use of animals in research.
Genotyping: Fresh tail snips (2 mm) were digested overnight
with  DirectPCR  tail  lysis  reagent  (Viagen  Biotech,  Los
Angeles, CA) containing 0.3 mg/ml of Proteinase K (Sigma,
St Louis, MO) at 55 °C. The lysates were incubated at 95 °C
for 5 min, and 2 μl of lysate was used per PCR reaction in
Green Go Taq master mix (Promega, Fitchburg, WI). The
fat-1 transgene was detected using primers (5′-CTG CAC
CAC GCC TTC ACC ACC C-3′ and 5′-ACA CAG CAG ATT
CCA GAG ATT-3′), which amplify a 251 bp product. A
separate  PCR  reaction  was  performed  to  detect  the  TG2
transgene using primers (5′-TAA GTG GGT TGC AGG AGG
AC-3′ and 5′-TTG GGG AAG GGG CAG TC-3′), which
amplify a 215 bp product. PCR products were visualized on
1.25% agarose gels.
Electroretinography:  Animals  kept  in  total  darkness
overnight were anesthetized with an intramuscular injection
of 120 mg/kg bodyweight ketamine and 6 mg/kg bodyweight
xylazine under dim red light. One drop of 10% phenylephrine
was applied to each animal’s cornea to dilate the pupil and one
drop  of  0.5%  proparacaine  HCl  was  applied  for  local
anesthesia. A reference electrode was positioned in the mouth
and  a  ground  electrode  on  the  tail.  Nine  different  flash
intensities, ranging from 0.001 to 2000 cd.s/m2, were used.
Electroretinogram  (ERG)  responses  from  both  eyes  were
recorded with gold electrodes placed on the cornea (Espion
E2 ERG System, Diagnosys, LLC, Lowell, MA). The a-wave
and b-wave amplitudes from each eye were determined and
averaged for comparison of retinal function.
Outer  nuclear  layer  thickness  measurement:  After  ERG
testing, anesthetized animals were euthanized by asphyxiation
with carbon dioxide. Right eyes were enucleated, fixed with
Perfix  (20%  isopropanol,  2%  trichloroacetic  acid,  4%
paraformaldehyde, and 2% zinc chloride) and embedded in
paraffin.  Next,  5  µm  thick  sections  were  taken  along  the
vertical meridian to allow comparison of all regions of the
retina in the superior and inferior hemispheres. In each of the
hemispheres,  outer  nuclear  layer  (ONL)  thickness  was
measured in nine defined areas, starting at the optic nerve head
and extending along the vertical meridian toward the superior
and inferior ora serrata. Measurements were made at 225 µm
intervals. Mean ONL thickness was then calculated for the
entire retinal section.
Lipid analysis: Fatty acid profiles were analyzed in whole
retina, liver, and plasma from Fat1+/TG2+, Fat1–/TG2+, Fat1+/
TG2–, and Fat1–/TG2– mice of C57BL/6J strains. One single
retina was taken for each analysis. Each plasma sample was
obtained by centrifuging the heparinized blood at 2,000x g in
EGTA-containing  tubes  to  obtain  approximately  100  µl
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1186plasma.  For  whole  retina  and  plasma,  total  lipids  were
extracted following the method of Bligh and Dyer [30]. The
tissues were extracted in chloroform:methanol:water (1:1:1)
and the chloroform phase collected. The remaining aqueous
phase was extracted once again with chloroform, keeping the
chloroform:methanol:water  ratios  at  1:1:1.  As  before,  the
chloroform  phase  was  collected  and  combined  with  the
chloroform phase from the initial extraction. The combined
chloroform  phases  were  then  extracted  with
chloroform:methanol:water (3:48:47) and the aqueous phase
discarded. The remaining purified lipid extract was stored
under nitrogen. For liver, total lipids were extracted following
the method of Folch et al. [31]. The tissues (n=3–4 mice per
group) were homogenized in 4 ml of chloroform:methanol
(2:1).  Proteins  in  the  homogenate  were  pelleted  by
centrifugation at 1,000x g for 10 min and the lipid extract was
removed.  The  pellet  was  washed  twice  with  1  ml  of
chloroform:methanol 1:1 and the washes were combined with
the lipid extract. The lipid extract was then washed with 0.2
volumes of 1 mM DTPA(aq) followed by 0.2 volumes of
Figure 1. Plasma fatty acid composition. Relative mole percentage
(±SD)  of  n3  and  n6  polyunsaturated  fatty  acids  are  from  total
phospholipids of plasma of Fat1+/TG2+, Fat1–/TG2+, Fat1+/TG2–,
and Fat1–/TG2– mice at age of 4 weeks (A; n=3–4) and 16 weeks
(B; n=4–6). Single (*), double (**), and triple (***) asterisks indicate
p<0.05, p<0.01, and p<0.001 for fat-1 positive versus fat-1 negative
values. *p<0.05 fat-1 positive versus fat-1 negative. Double asterisk
(**) indicates a p<0.01 fat-1 positive versus fat-1 negative. Triple
asterisk  (***)  represents  a  p<0.001  fat-1  positive  versus  fat-1
negative.
chloroform:methanol:water (3:48:47), each time discarding
the aqueous phase. The resulting purified lipid extract was
dried under nitrogen and re-suspended in a known volume of
toluene. Purified lipid extracts from plasma and liver were
resolved into individual lipid classes using one-dimensional
thin-layer chromatography. Briefly, an aliquot of each extract
was spotted onto 10×20 cm Silica Gel 60 plates (EM Science,
Gibbstown, NJ). Lipid classes were resolved hexane:etyhy
ether: glacial acetic acid (70:30:2.3, by vol) acid mobile phase,
and  plates  were  stained  with  0.05%  (wt/vol)  2,7-
dichlorofluorescein in 75% (vol/vol) methanol. Fatty acids of
purified lipid extracts of whole retina and of scraped thin-layer
chromatography spots from plasma and liver extracts were
derivatized to form fatty acid methyl esters and analyzed using
gas-liquid chromatography. The fatty acid compositions were
determined by injecting 3 µl of each sample at 250 °C with a
split ratio of 20:1 (10:1 for whole retina) onto a (30 m long x
0.32 mm I.D.) DB-225 capillary column (J&W Scientific,
Folsom, CA) in an Agilent 6890N gas chromatograph with
model 7683 autosampler (Agilent Technologies, Wilmington,
DE). The column temperature was programmed to begin at
160 °C, ramped to 220 °C at 1.33 °C/min, and held at 220 °C
for 18 min. Hydrogen carrier gas was allowed to flow at
1.6 ml/min, and the flame ionization detector temperature was
set to 270 °C. The chromatographic peaks were integrated and
processed  with  ChemStation®  software  (Agilent
Technologies).  FAMES  were  identified  by  comparison  of
their relative retention times with authentic standards (NU-
CHEK PREP, Elysian, MN) and relative mole percentages
were calculated.
Rhodopsin  assay:  Mice  were  dark-adapted  overnight  and
euthanized  under  dim  red  light  by  carbon  dioxide
asphyxiation. One eye was removed from each animal and
homogenized  in  buffer  containing  10  mM  Tris  (pH  7.4),
150 mM NaCl, 1mM EDTA, 2% (wt/vol) octylglucoside, and
50 μM hydroxylamine. Homogenates, maintained in dim red
light, were centrifuged at 16,000x g, and the soluble fractions
were scanned from 270 to 800 nm in an Ultrospec 3000 UV/
Vis spectrophotometer (GE Healthcare, Piscataway, NJ). The
samples were subsequently bleached by exposure to room
light  (approximately15  min)  and  scanned  again.  The
difference in absorbance at 500 nm between unbleached and
postbleached  samples  was  used  to  determine  rhodopsin
content, using a molar extinction coefficient of 42,000 M–1
[32].
Statistical analysis: Results are expressed as the mean±SD.
Differences were assessed by multivariant ANOVA followed
by Neuman-Keuls posthoc test. A p<0.05 was considered
significant.
RESULTS
Fatty acid composition of plasma, liver, and retina: Mice
expressing the fat-1 gene can efficiently convert n6 to n3
PUFA in all tissues that express the gene. Since none of the
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1187dams expressed fat-1 and all were fed the SFO diet before
conception,  only  the  pups  expressing  fat-1  were  able  to
synthesize  n3  PUFA.  This  allowed  the  development  of  a
model  in  which  membrane  PUFA  content  could  be
manipulated in littermates fed the same diet thus reducing
variability due to differences in diet and genetic background.
Figure 1 and Figure 2 show the fatty acid compositions of the
total phospholipids from plasma and liver, respectively, while
Figure 3 shows the fatty acid composition of the total lipid
extract from retina. In general, the mice expressing fat-1 had
higher  percentages  of  22:6n-3  (p<0.001)  and  lower
percentages  of  20:4n-6  (p<0.05  to  approximately  0.01),
22:4n-6 (p<0.001), and 22:5n-6 (p<0.001); 20:5n-3 could not
be detected in the fat-1 negative mice. These differences were
already established by 4 weeks of age and did not change
appreciably over the ensuing 12 weeks. The expression of the
TG2 transgene did not affect the fatty acid composition of any
of the three tissues that were examined.
The levels of retinal DHA in the fat-1 negative mice were
roughly half of that in fat-1 expressing mice (Figure 3). As
reported previously by many laboratories, reduction in DHA
in the retina was accompanied by a near-equivalent increase
in 22:5n6 [11,18,19,33-35]. Even though the dams were fed a
Figure 2. Liver fatty acid composition. Relative mole percentage
(±SD)  of  n3  and  n6  polyunsaturated  fatty  acids  are  from  total
phospholipids of plasma of Fat1+/TG2+, Fat1–/TG2+, Fat1+/TG2–,
and Fat1–/TG2– mice at age of 4 weeks (A; n=4–5) and 16 weeks
(B; n=4–7). Single (*), double (**), and triple (***) asterisks indicate
p<0.05, p<0.01, and p<0.001 for fat-1 positive versus fat-1 negative
values Single asterisk (*) indicates a p<0.05 fat-1 positive versus
fat-1 negative. Double asterisk (**) represents a p<0.01 fat-1 positive
versus fat-1 negative. Triple asterisk (***) indicates a p<0.001 fat-1
positive versus fat-1 negative.
SFO diet before conception, the retinas of the fat-1 negative
mice still contained relatively high levels of n3 PUFA. This
is not surprising, since neural tissues accumulate n3 PUFA
from their mothers in utero and during the 3-week nursing
period before weaning. Maintenance of these levels of n3
PUFA at 16 weeks of age is consistent with earlier studies
showing  that  the  retina  has  an  efficient  mechanism  of
conserving n3 PUFA by recycling from the retinal pigment
epithelium [25].
Effect of DHA levels on retinal structure: Retinal structure
was examined along the vertical meridian from inferior to
superior  ora  serrata;  representative  sections  from  central
superior retina are shown in Figure 4. At 4 weeks of age, there
was a slight loss of rod photoreceptors in TG2 positive (T+)
mice that also expressed fat-1 (F+; Figure 4A). By 16 weeks
of age,  there was a significant  thinning of  the ONL of both
+  T groups compared to the T–  groups. The presence of higher
Figure 3. Retina Fatty Acid Composition. Relative mole percentage
(±SD)  of  n3  and  n6  polyunsaturated  fatty  acids  are  from  total
phospholipids of plasma of Fat1+/TG2+, Fat1–/TG2+, Fat1+/TG2–,
and Fat1–/TG2– mice at age of 4 weeks (A; n=3–5) and 16 weeks
(B; n=5–6). Single (*), double (**), and triple (***) asterisks indicate
p<0.05, p<0.01, and p<0.001 for fat-1 positive versus fat-1 negative
values.
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1188levels of DHA in the T+/F+ group (Figure 4A,E) had no effect
on rod photoreceptor survival.
Quantification of age-related loss of rod photoreceptors
at each point measured along the vertical meridian is presented
in the “spider” graphs in Figure 5A,C. Photoreceptor nuclei
were lost in both inferior and superior regions of the mice
expressing  the  ELOVL4  transgene  compared  to  controls,
especially at 16 weeks of age. Mean ONL thicknesses taken
from 14 sites along the vertical meridian (7 superior and 7
inferior of the optic nerve head) were calculated for both age
groups.  There  were  no  significant  differences  in  ONL
thickness between F+/T+ versus F–/T+ and F+/T– versus F–/T–
mice at 4 and 16 weeks of age. However, compared to 4-week-
old T+ mice (Figure 5B), ONL thickness was reduced 31% in F
+ mice and 32% in F– mice at 16 weeks of age (Figure 5D).
Effect of DHA levels on retinal function: ERG was used to
detect  retina  function  for  both  age  groups.  Nine  different
intensity flashes, ranging from 0.001 to 2,000 cd.s/m2, were
used (Figure 6A,B,E,F) and ERG responses from both eyes
were  recorded  and  averaged.  The  amplitudes  of  mice  at
saturating flash intensity, 1,000 cd.s/m2, are shown in Figure
6C,D,G,H. As expected, ERG a-wave responses were reduced
at  16  weeks  of  age  in  the  mice  expressing  the  ELOVL4
transgene, reflecting the significant degeneration observed by
histology and morphometry. However, we observed no effect
of DHA levels on the response amplitudes of the ERG of T+
or T– mice. The amplitudes of a-waves in the T+ mice were
already slightly lower than those in T– mice at 4 weeks of age
(Figure 6A,C), although there were no differences in the b-
waves  (Figure  6E,G).  There  was  a  significant  age-related
Figure 5. Quantification of morphologic changes in transgenic mice.
Measurements of ONL thickness (±SD) were made along the vertical
meridian of the eye in Fat1+/TG2+, Fat1–/TG2+, Fat1+/TG2–, and
Fat1–/TG2– mice maintained in 20 lx cyclic light (n≥8). A, C:
Averages were made of ≥8 retinas of transgenic mice at 4 and 16
weeks of age. B, D: The histograms are the average ONL thickness
at both age groups.
Figure 4. Retinal structure in transgenic
mice. Representative photomicrographs
are from the central superior retina of
Fat1+/TG2+,  Fat1–/TG2+,  Fat1+/
TG2–, and Fat1–/TG2– mice at 4 weeks
(A-D) and 16 weeks of age (E-H).
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1189reduction in both a-wave and b-wave amplitudes of all four
groups (Figure 6). Interestingly, the a-wave amplitudes, but
not the b-wave amplitudes, of 16-week-old T+ mice were
lower than those of T– mice.
Effect of DHA on rhodopsin levels: Figure 7 shows the levels
of bleachable rhodopsin in the four experimental groups of
mice. There was already some reduction in rhodopsin levels
at 4 weeks of age in the T+ mice compared to T– mice. This
reduction  was  even  more  dramatic  at  16  weeks  of  age,
corresponding to the loss of photoreceptors demonstrated by
our ONL thickness measurements (Figure 5). However, as
was the case in our morphometric and functional analyses,
DHA levels had no effect on the rhodopsin content in T+ or
T– mouse retinas.
DISCUSSION
The fat-1 transgene provides the opportunity to significantly
alter the membrane content of n3 and n6 PUFA in animals
derived from the same dam and fed the same diet [29]. In the
current study, we produced mice with dramatically different
Figure 6. Evaluation of functional changes by electroretinography.
Measurements of ERG a- and b-wave amplitudes (±SD) were made
in Fat1+/TG2+, Fat1–/TG2+, Fat1+/TG2–, and Fat1–/TG2– mice
maintained in 20 lx cyclic light (n≥10). The a-wave (A, B) and b-
wave (E, F) amplitudes are from nine flash intensities at 4 weeks and
16 weeks. C, D are the average a-wave amplitudes of transgenic mice
at 4 weeks and 16 weeks of age. E, H are b-wave amplitudes.
retinal DHA levels that also expressed the transgene encoding
one of the ELOVL4 mutations found in patients with STGD3
[6]. Mice expressing the fat-1 transgene, fed an n3-deficient
SFO diet, produced large amounts of n3 PUFA, resulting in
significantly higher levels of DHA in retina, liver, and plasma
as  was  found  in  our  earlier  light  damage  study  [29].  As
expected, retinas showed the highest level of DHA. Mice
without  fat-1  expression  fed  the  SFO  diet  had  fatty  acid
profiles similar to those reported in other studies of n3 dietary
deficiency [11,18,19,33-35], namely a decrease in DHA that
was offset by an increase in 22:5n6. It is interesting that the
retinas of fat-1 negative mice (wild type) had relatively high
levels of DHA (although still half those of the fat-1 positive
mice), even though their dams had been fed the SFO diet well
before conception. This illustrates the striking ability of the
retina and the retinal pigment epithelium to sequester DHA
from the blood and to conserve it in the retina by a highly
efficient recycling system between the two tissues [25,36].
The gene mutation responsible for autosomal dominant
Stargardt macular dystrophy, first described in 2001 [2], was
found to have significant sequence homology to a family of
fatty acid elongases [2], all of which catalyze the condensing
reaction responsible for 2-carbon elongation of fatty acids.
Figure 7. Rhodopsin content in transgenic mice. Rhodopsin content
was determined in eyes (±SD, n≥4) from Fat1+/TG2+, Fat1–/TG2+,
Fat1+/TG2–, and Fat1–/TG2– mice at age of 4 weeks (A) and 16
weeks (B).
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1190These reactions occur on the endoplasmic reticulum and each
ELOVL  enzyme  (including  ELOVL4)  has  a  C-terminal
endoplasmic reticulum retention motif [7]. The265 mutated
ELOVL4 gene product is truncated and no longer contains the
endoplasmic reticulum signal [37-39], so it is possible that the
effect of the mutation is interference with fatty acid elongation
in the retina and other tissues in which the gene is expressed.
It was suggested that the metabolic defect in STGD3 might be
in the elongation of shorter chain n3 PUFA to DHA [2], since
it is the major fatty acid in the retina and rod outer segments
[9], and numerous studies in animals [10,11,14-19,21,34,40]
and humans [12,13,20] have shown that DHA is essential for
optimal development and function of the retina. We now know
that  ELOVL4  is  not  involved  in  DHA  synthesis,  as  we
recently  showed  that  it  catalyzes  the  elongation  of  C26
saturated and polyunsaturated fatty acids to C28-C38 fatty
acids  [41].  Nevertheless,  it  remained  to  be  determined  if
retinal DHA also played a role in the retinal degenerative
process that occurs in STGD3, since two studies in patients
had  suggested  a  potentially  beneficial  role  [22,23].  The
current study is also important since the AREDSII clinical trial
has  DHA  and  eicosapentaenoic  acid  (20:5n3)
supplementation as one of its variables.
There was a significant reduction in the amplitudes of the
a-waves and b-waves of the ERG as a function of age (Figure
6), with the greatest relative reduction occurring in the a-wave.
A similar result was reported by Li et al. [42] in C57BL/6 mice
at ages 2, 6, and 12 months. Although not discussed, there
appeared to be a relatively greater loss of a-wave amplitude
in their study as well. They could not explain the loss, but
suggested that it could be due to decreased resistance as a
function of age. This explanation seems reasonable, since the
ERG is a measure of electrical activity of the retina, and
significant growth occurs between 4 and 16 weeks—the age
of the mice used in our study. Lee and Flannery [43] also noted
an age-related reduction in ERG amplitudes in heterozygous
rhodopsin knockout mice, with the greatest relative change
occurring in the a-wave. In our study, we fed a special diet
devoid  of  n3  PUFA.  However,  our  observations  of  ERG
changes is not likely related to diet, since the observations of
Li et al. [42] and Lee and Flannery [43] were made on animals
fed laboratory chow diets.
The results of our study show that high DHA levels in the
retinas  of  mice  overexpressing  the  mutated  ELOVL4
transgene do not slow or prevent the retinal degeneration.
Although the retinal levels of DHA in the fat-1 positive mice
were twice those of the wild-type animals fed an n3-deficient
diet, there was no effect of DHA on the structure or function
of the retina. We therefore conclude that in the animal model
we used, namely a transgenic mouse overexpressing mutant
human ELOVL4 along with two normal mouse copies, DHA
does not rescue structure or function of rod photoreceptors.
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